Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 study of tenofovir alafenamide versus placebo added to a failing HIV regimen, followed by E/C/F/TAF plus atazanavir
2013-002830-19Phase 3Completed
- Sponsor
- Gilead Sciences
- Start
- Sep 2013
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised trial of tenofovir alafenamide in Human immunodeficiency virus infection type 1 (3 arms), sponsored by Gilead Sciences. Primary endpoint: Proportion of subjects with plasma HIV-1 RNA decrease greater than 0.5 log10 at Day 10. Started Sep 2013; status: completed.
02
Drugs
tenofovir alafenamide
03
Conditions
Human immunodeficiency virus infection type 1
Beyond the preview
Go deeper on 2013-002830-19.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2013-002830-19.